News and Trends 6 Jul 2015
ElsaLys Biotech grabs MABLife’s dual-acting antibody to treat cancer
French ElsaLys Biotech just acquired MABLife’s anti-CD160 antibody. Originally developed for the treatment of vascular eye diseases, the antibody also has the potential to be applied for tumor therapy. It inhibits vascular proliferation and modulates the immune system. To proliferate and migrate through the body, tumors rely on oxygen and nutrients supplies. Cancer cells initiate […]